iCoat Medical

Executive Summary

iCoat Medical is a Swedish pharmaceutical company dedicated to addressing the critical unmet need of ischemia-reperfusion injury (IRI) in organ transplantation. Founded in 2015 and headquartered in Stockholm, the company leverages over 25 years of academic research to develop its lead candidate, iCM012, a small molecule designed to reduce and prevent IRI. This condition affects transplanted organs during recovery of blood flow, leading to poor outcomes and limiting organ availability. By mitigating IRI, iCoat aims to improve transplant success rates and expand the pool of usable donor organs, potentially transforming the field of transplantation. The company is currently in the preclinical stage, with iCM012 progressing through advanced animal studies. Its innovative approach targets multiple pathways involved in IRI, offering a differentiated mechanism compared to existing therapies. iCoat has operations in Uppsala, Lund, Malmö, and Tsukuba, Japan, indicating a global research footprint. While detailed financials and specific trial timelines are not publicly available, the company's strong scientific foundation and focus on a high-impact area position it for potential milestones, including IND-enabling studies and strategic partnerships. Successful development could lead to a significant commercial opportunity given the large transplant market.

Upcoming Catalysts (preview)

• Q2 2026Completion of preclinical efficacy studies for iCM01280% success
• Q4 2026Initiation of IND-enabling toxicology studies70% success
• 2027Potential partnership or licensing deal for iCM01260% success